Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells

Drug Discovery Today

Volumn 12, Issue 7-8, 2007, Pages 319-326

  Byrne, Barry ^a   Donohoe, Gerard G ^a   O'Kennedy, Richard ^a  

^a School of Biotechnology   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ASCITES SIALOGLYCOPROTEIN 1; ASPARAGINASE; CHOLINESTERASE; CHORIONIC GONADOTROPIN; EPITOPE; FOLLITROPIN; GLYCAN; GLYCOPHORIN A; GLYCOPHORIN C; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 20; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; LEPTIN; LUTEINIZING HORMONE; MG 160; N GLYCOLOYLNEURAMINIC ACID; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OSTEOPONTIN; PROTEIN; RECOMBINANT ERYTHROPOIETIN; SIALIC ACID; THYROTROPIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

CHEMICAL REACTION; COVALENT BOND; DRUG HALF LIFE; HUMAN; IMMUNOGENICITY; NONHUMAN; PEGYLATION; REACTION ANALYSIS; REVIEW; SIALYLATION;

ANIMALS; DRUG DESIGN; DRUG INDUSTRY; EUKARYOTIC CELLS; GLYCOPROTEINS; HUMANS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PROKARYOTIC CELLS; SIALIC ACIDS;

EID: 33947545682     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.02.010     Document Type: Review

References (64)

1. Werle M., and Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30 (2006) 351-367
2. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2 (2003) 214-221
3. Graham M.L. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 55 (2003) 1293-1302
4. Levy Y., et al. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J. Pediatr. 113 (1988) 312-317
5. DeFrees S., et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 16 (2006) 833-843
6. Caliceti P., and Veronese F.M. Pharmokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55 (2003) 1261-1277
7. Veronese F.M., and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005) 1451-1458
8. Blix G., et al. Proposed nomenclature in the field of neuraminic and sialic acid. Nature 179 (1957) 1088
9. Angata T., and Varki A. Chemical diversity in the sialic acids and related α-keto acids: an evolutionary perspective. Chem. Rev. 102 (2002) 439-469
10. Razi N., and Varki A. Cryptic sialic acid binding lectins on human blood leukocytes can be unmasked by sialidase treatment or cellular activation. Glycobiology 9 (1999) 1225-1234
11. Varki A., and Angata T. Siglecs - the major subfamily of I-type lectins. Glycobiology 16 (2006) 1R-27R
12. Shinya K., et al. Avian flu: influenza virus receptors in the human airway. Nature 440 (2006) 435-436
13. Traving C., and Schauer R. Structure, function and metabolism of sialic acids. Cell. Mol. Life Sci. 54 (1998) 1330-1349
14. Mühlenhoff M., et al. Polysialic acid: three-dimensional structure, biosynthesis and function. Curr. Opin. Struct. Biol. 8 (1998) 558-564
15. Kiss J.Z., and Rougon G. Cell biology of polysialic acid. Curr. Opin. Neurobiol. 7 (1997) 640-646
16. 2+, phosphoenolpyruvate, and N-acetylmannosaminitol. J. Biol. Chem. 280 (2005) 3555-3563
17. Deszo E.L., et al. Escherichia coli K1 polysialic acid O-acetyltransferase gene, NeuO, and the mechanism of capsule form variation involving a mobile contingency locus. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5564-5569
18. Coquillat D., et al. Activity and cross-reactivity of antibodies induced in mice by immunization with a group b meningococcal conjugate. Infect. Immun. 69 (2001) 7130-7139
19. Weiss P., and Ashwell G. Ligand-induced modulation of the hepatic receptor for asialoglycoproteins. Evidence for the role of cell surface hyposialylation. J. Biol. Chem. 264 (1989) 11572-11574
20. Jain S., et al. Polysialylation: The natural way to improve the stability and pharmokinetics of protein and peptide drugs. Drug Delivery Systems and Sciences 4 (2004) 59-65
21. Gregoriadis G., et al. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int. J. Pharm. 300 (2005) 125-130
22. Fernandes A.I., and Gregoriadis G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int. J. Pharm. 217 (2001) 215-224
23. Elliott S., et al. Structural requirements for additional N-linked carbohydrate on recombinant human erythropoietin. J. Biol. Chem. 279 (2004) 16854-16862
24. Burgon P.G., et al. In vivo bioactivities and clearance patterns of highly purified human luteinizing hormone isoforms. Endocrinology 137 (1996) 4827-4836
25. Saxena A., et al. Structure of glycan moieties responsible for the extended circulatory life time of fetal bovine serum acetylcholinesterase and equine serum butyrylcholinesterase. Biochemistry 36 (1997) 7481-7489
26. Egrie J.C., and Browne J.K. Development and characterization of novel erythpoiesis stimulating protein (NESP). Br. J. Cancer 84 Suppl. 1 (2001) 3-10
27. Egrie J.C., et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 31 (2003) 290-299
28. Andersen D.C., and Krummen L. Recombinant protein expression for therapeutic applications. Curr. Opin. Biotechnol. 13 (2002) 117-123
29. Helenius A., and Aebi M. Intracellular functions of N-linked glycans. Science 291 (2001) 2364-2369
30. MacDougall I.C., et al. Pharmokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol. 10 (1999) 2392-2395
31. MacDougall I.C. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol. Dial. Transplant. 16 Suppl. 3 (2001) 14-21
32. Wide L., et al. A new principle suggested for detection of darbepoetin - alpha (NESP) doping. Ups. J. Med. Sci. 108 (2003) 229-238
33. Glaspy J., et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br. J. Cancer 84 Suppl. 1 (2001) 17-23
34. Lee E.U., et al. Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of beta-galactoside alpha 2,6-sialyltransferase. J. Biol. Chem. 264 (1989) 13848-13855
35. Minch S.L., et al. Tissue plasminogen activator coexpressed in Chinese hamster ovary cells with alpha (2,6)-sialyltransferase contains NeuAc alpha(2,6)Gal beta(1,4)Glc-N-AcR linkages. Biotechnol. Prog. 11 (1995) 348-351
36. Bragzoni A., et al. A new Chinese hamster ovary cell line expressing alpha 2,6-sialyltransferase used as universal host for the production of human-like sialylated recombinant glycoproteins. Biochim. Biophys. Acta 1474 (2000) 273-282
37. Fukuta K., et al. Genetic engineering of CHO cells producing human interferon-gamma by transfection of sialyltransferases. Glycoconj. J. 17 (2000) 895-904
38. Jassal R., et al. Sialylation of human IgG-Fc carbohydrate by transfected rat alpha 2,6-sialyltransferase. Biochem. Biophys. Res. Commun. 286 (2001) 243-249
39. Nakagawa K., et al. Sialylation enhances the secretion of neurotoxic amyloid-beta peptides. J. Neurochem. 96 (2006) 924-933
40. Wong N.S.C., et al. Enhancing recombinant glycoprotein sialylation through CMP-sialic acid transporter over expression in Chinese hamster ovary cells. Biotechnol. Bioeng. 93 (2006) 1005-1016
41. Galbraith D.J., et al. Control of culture environment for improved polyethylenimine-mediated transient production of recombinant monoclonal antibodies by CHO cells. Biotechnol. Prog. 22 (2006) 753-762
42. Wildt S., and Gerngross T.U. The humanization of N-glycosylation pathways in yeast. Nat. Rev. Microbiol. 3 (2005) 119-128
43. Gu X., and Wang D.I. Improvement of interferon-gamma sialylation in Chinese hamster ovary cell culture by feeding of N-acetylmannosamine. Biotechnol. Bioeng. 58 (1998) 642-648
44. Hills A.E., et al. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells. Biotechnol. Bioeng. 75 (2001) 239-251
45. Baker K.N., et al. Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells. Biotechnol. Bioeng. 73 (2001) 188-202
46. Gramer M.J., and Goochee C.F. Glycosidase activities in Chinese hamster ovary cell lysate and cell culture supernatant. Biotechnol. Prog. 9 (1993) 366-373
47. Gramer M.J., et al. Removal of sialic acid from a glycoprotein in CHO cell culture supernatant by action of an extracellular CHO cell sialidase. Biotechnology (N.Y.) 13 (1995) 692-698
48. Ngantung F.A., et al. RNA interference of sialidase improves glycoprotein sialic acid content consistency. Biotechnol. Bioeng. 95 (2006) 106-119
49. Jahn M., et al. Thioglycoligases: mutant glycosidases for thioglycoside synthesis. Angew. Chem. Int. Ed. Engl. 42 (2003) 352-354
50. Müllegger J., et al. Glycosylation of a neoglycoprotein by using glycosynthase and thioglycoligase approaches: the generation of a thioglycoprotein. Angew. Chem. Int. Ed. Engl. 45 (2006) 2585-2588
51. Chou H.H., et al. Inactivation of CMP-N-acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11736-11741
52. Tangvoranuntakul P., et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12045-12050
53. Nguyen D.H., et al. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J. Immunol. 171 (2005) 228-236
54. Martin M.J., et al. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat. Med. 11 (2005) 228-232
55. Bardor M., et al. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J. Biol. Chem. 280 (2005) 4228-4237
56. Gerngross T.U. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat. Biotechnol. 22 (2004) 1409-1414
57. Bretthauer R.K. Genetic engineering of Pichia pastoris to humanize N-glycosylation of proteins. Trends Biotechnol. 21 (2003) 459-462
58. Hamilton S.R., et al. Production of complex human glycoproteins in yeast. Science 301 (2003) 1244-1246
59. Hamilton S.R., et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313 (2006) 1441-1443
60. Harris A.G. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 35 Suppl. 3 (1994) S1-S4
61. Brinckerhoff L.H., et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int. J. Cancer 83 (1999) 326-334
62. Rozek A., et al. Structure-based design of an indolicidin peptide analogue with increased protease stability. Biochemistry 42 (2003) 14130-14138
63. Syed S., et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 89 (1997) 3243-3252
64. Osborn B.L., et al. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur. J. Pharmacol. 456 (2002) 149-158